Pacific Biosciences
PACB
SEC CIK 1299130 LEI 529900F1BWRE1M0KZN89
Follow Pacific Biosciences
Weekly email: filings, results
Revenue, last quarter
$40.6M
+5.5% vs same quarter last year
Net income
−$37.8M
+0.4% vs same quarter last year
EPS, diluted
−$0.12
+7.7% vs same quarter last year
Operating cash flow
−$37.6M
−101% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $160M | −$546.4M |
| FY24 | $154M | −$309.9M |
| FY23 | $200.5M | −$306.7M |
| FY22 | $128.3M | −$314.2M |
| FY21 | $130.5M | −$181.2M |
| FY20 | $78.9M | $29.4M |
| FY19 | $90.9M | −$84.1M |
| FY18 | $78.6M | −$102.6M |
| FY17 | $93.5M | −$92.2M |
| FY16 | $90.7M | −$74.4M |
| FY15 | $92.8M | −$31.7M |
| FY14 | $60.6M | −$66.2M |
| FY13 | $28.2M | −$79.3M |
| FY12 | $26M | −$94.5M |
| FY11 | $33.9M | −$109.4M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 28.6% | −346.2% | −341.5% |
| FY24 | 24.2% | −308% | −201.2% |
| FY23 | 26.3% | −166.8% | −153% |
| FY22 | 38.2% | −239.4% | −244.9% |
| FY21 | 45.1% | −161.2% | −138.8% |
| FY20 | 41.3% | −132.3% | 37.3% |
| FY19 | 38% | −110.6% | −92.6% |
| FY18 | 31.9% | −128.4% | −130.4% |
| FY17 | 37.1% | −96.1% | −98.6% |
| FY16 | 48.7% | −78.5% | −82% |
| FY15 | 57.6% | −31.4% | −34.2% |
| FY14 | 38.6% | −103.7% | −109.2% |
| FY13 | 22.8% | −275.2% | −281.4% |
| FY12 | 3.6% | −363.1% | −363.6% |
| FY11 | 38.5% | −324.1% | −323% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$113.9M |
| FY24 | −$212.2M |
| FY23 | −$268M |
| FY22 | −$280M |
| FY21 | −$117.1M |
| FY20 | $18.5M |
| FY19 | −$81.1M |
| FY18 | −$68.3M |
| FY17 | −$78M |
| FY16 | −$76.1M |
| FY15 | −$50.9M |
| FY14 | −$53.1M |
| FY13 | −$30.7M |
| FY12 | −$78.5M |
| FY11 | −$112.3M |